The share of the Belgian-Dutch Galapagos Islands was severely punished on Wednesday on the stock exchanges in Brussels and Amsterdam after a setback from the rheumatism of the biotech company in the USA.
The Galapagos rheumatic drug filgotinib is not yet ready for approval in its current form. The American Food and Drug Administration (FDA) has reported this to the Galapagos partner Gilead. Galapagos speaks in response to a setback. Upon approval of the drug, the company would receive a milestone payment of $ 100 million.
The news initially caused a decrease of 32 percentage points (from 116.70 euros to 105.30 euros). At 11 a.m. this decrease had been reduced to 25.5 pieces.